Objective: To evaluate the quality of management of oral anticoagulation among patients on oral anticoagulation for atrial fibrillation, and to verify the relation between patient performance and the risk of an event due to therapy. Methods: In a retrospectivecross-sectional study involving 66 general practices, international normalized ratio (INR) values obtained over a6 -mo period were analysed. All INR values were determined by as ingle clinical laboratory, and additional medical information was provided by GPs. Results: 395 patients were included in the study,w ith am ean age of 749 / 9.6 y. In total, 3111 INR values were obtained. The mean number of tests/month per patient was 2.79 / 4.3. Atotal of 49 728 doftherapy was evaluated. Fifty-three per cent of the day values were within 0.5 INR units of the target (and 69% within 0.75 INR units of the target). The incidence rate for major bleeding was 4.4/100 patient years (and 2.9/100 patient years for thromboembolic events). There was as ignificant relation between patient performance and the presence of an event ( p / 0.017), with an odds ratio of 2.8 (95% CI 1.3 6.3).
Introduction
Recent yearsh aves een an increase in interest in the management of oral anticoagulation. Principally,this has been driven by the increasing numbers of patientsr eceiving oral anticoagulation as ar esult of trials demonstratingt he effectiveness of this treatment in preventing strokes in patientsw ith atrial fibrillation (AF) (1, 2) .H owever, the risk of therapy with oral anticoagulants is high because of the following factors: the narrow therapeutic range of the anticoagulants, patient characteristics, and the variable quality of care dependingo nt he management system.
Deviation from the therapeutic rangei sa ni mportant causeo ft reatment failure, including both thrombosisa nd haemorrhage. Cannegieter et al. found an increasing risk of haemorrhage or thrombosis when the international normalized ratio (INR) was aboveorbelow the therapeutic range of 2.5 4.9 (3). Vand er Meer et al. found that the risk of major bleeding increased by 42% for each one-point increase in the INR (4) . According to the third edition of the guidelines on oral anticoagulation, the target INRf or patients with AF is 2.5 (5) . The following quality criteria are defined: 50% of the INR resultso ft he patient population shouldb e within the range of 2 3( and 80% within the INR range of 1.75 3.25). Several studies found an increase of bleeding with age and the dependence of bleeding frequencyo nt he type of coumarin derivative used (4,6 8) . The quality of supervision of the anticoagulation therapy by the physician is the third risk factor determining the occurrence of adverse events.I nt he Netherlands, the follow-up of the therapy is performed in anticoagulation clinics (9) . The UK has am ixed system, the anticoagulant dosing being prescribed by the anticoagulation clinic rather thanb yG Ps (10) . In Germany,m ore than 90% of orally anticoagulated patients are controlled by the GP (11) . As in Germany,the management of oral anticoagulation in Belgium is mainly performed by the GP.Avenous blood sample is taken by the GP at the patient'sh omeo ri nt he office. Blood analysis is performed by an external laboratory. After obtaining the INR, the patient receives information from the GP regarding the dosage for the following days or weeks.T he dosing and nextd ate for INR control is based on the GP'sc linical judgement.
Ar etrospective study of 15 GPs in Belgium showed 58% of the results withint he target INR interval of 2 3( target INR 2.5), and 68.38% within 1.75 3.25 (12) . The aim of this crosssectional study was to analyse the quality of the management of oral anticoagulation in patients with AF,a nd to verifyt he relationb etween patient performance andr isk of haemorrhagico rt hromboembolic events.
Methods

Population
All 255 GPs whos end blood samples for analysis to the clinical laboratoryatthe Medical Centre for GPs in Te ssenderlo (the northernp arto ft he province of Limburga nd the westernp arto ft he province of Antwerp, action rate 100 km) were invited to participate in the study.I nt otal, 96 GPs (response rate of 38%) were enrolled in the study (71 males and 25 females). No significant difference in gender, age and type of practice was found between the participating GPs and the non-participating GPs. Of the 96 participating GPs,5 2w ere working in group practiceand 44 were working in single practice. The mean number of yearsa fter graduation for the GPs was 18 y. Nine per cent of the GPs had been educated in oral anticoagulationw ithin the year before the study.E ighty-one per cent graduated at the University of Leuven, 9% at the University of Antwerp, 6% at the University of Gent and 3% at the University of Brussels. Threes essions were organizedt ot rain the GPs in filling in patient anticoagulation files.D uring these sessions, the aim of the study andt he definition of events were explained. The group practices counted for one entity; this resulted in 66 GP practices being includedi nt he study.
Patients
Al ist of all patientsf rom the co-operating GPs who had had more than one INR determination during the 6-mo study period was generated by the laboratoryc omputer. This list of patient names was sent to the general practitioner, who was asked to fill in an anticoagulation file for each patient. Only patientsa nticoagulated for atrial fibrillation were included. The patientsw ere entered intot he study as soon as they were in as teady state after the initial startu po ft herapy. This initial start-up period was considered to be 28 df or all oral anticoagulants, starting doses and schemes. Patients who needed to discontinue the anticoagulation therapy for as urgical procedure during the registration period were droppedf rom the study.A ll lethal/severe/minor bleedings, thromboembolic complications or hospitalizations during this period had to be declared.
Study design
The study consists of ar etrospective analysis of all INR determinations that were requested by the co-operating general practitioners. The primary outcomem easure was quality of anticoagulation management, defined as the percentage of time that INR values were withint heir target ranges. This was calculated accordingt oR osendaal'sa lgorithms, assuming al inear increase or decrease between two consecutive INR determinations. This percentage was calculated on the group and on the patient level. The latter implies the possibility of classifying the patients as poor ( B / 50% of INR day valueswithinI NR range of 2 3; B / 80% withinI NR range of 1.75 3.25) or good ( / 50% withinI NR range of 2 3; / 80% within INR range of 1.75 3.25) performers. Secondaryo utcomem easures were the numbero ft hromboembolic complications and the numbero fh aemorrhages. The complications were classified according to severity,a nd were defined according to the European Atrial Fibrillation Trial (20) .
Approval was obtained from the ethics committee of the Catholic University Hospital Leuven, and signed informed consent was obtained from each general practitioner before the starto ft he study.I n accordance with Belgian law,the study was reported to the Belgian Commission for the Protectiono f Privacy,c ontrolling for the private manipulation of patients data (name and address)i nt he study.
Analysis
In the descriptive analysis, the mean and interquartile range were calculated. Linearmixed models were used to model the percentage INR within the target range as af unction of different covariates and factors. This means that, in order to take into account the dependencyb etween patients of the same GP,t he GP was added to the model as a random effect. The relation between patient performance and the presence of an event was analysed with ar andom-effectl ogistic regression model (with GP as the randomeffect). The alpha level was set at 5%. All analysesw ere performed with the statistical package SAS (version 8.2), using the procedure PROC MIXEDf or the linear mixed model and PROC NLMIXEDf or the random-effectl ogistic regression.
Results
Patient characteristics
Three hundred andn inety-five patientsw ere included in the study: 51% were males ( n / 200) and 49% were females ( n / 195).T he mean age of the patientsw as 74 y( interquartile range (IQR)6 8 80 y). The risk factorsf or stroke andt he occurrence of thromboembolic complications or bleedings were as follows: 239 patientsh ad hypertension, 69 diabetes mellitus, 100 ap rior strokeo rt ransient ischaemic attack, 61 peripheral vascular disease, 144 congestive heartf ailure, 54 ap revious myocardial infarction, 98 av alved isease, 19 ah istoryo f malignancy, and 45 were smokers.T hreeh undred and thirty-six patientsw ere anticoagulated using phenprocoumon, 39 used acenocoumarol, 14 used warfarin, and in six patients the anticoagulant was unknown. The mean number of patientsp er GP practicew as 7( IQR 3 8).
Proportion of time that INRv alues were within their target ranges
The average follow-up perp atient,i ncluding patients on short-andl ong-terma nticoagulation, was 4mo(IQR 3. (Table I ). Figure 1s hows the distribution of the INRs: 8.7% were below the target range and3 8.5% were abovet he target range; 2.8% of the patient days gavea nI NR / 5. Fora nI NR range of 2 3, 213 were more than 50% withint his range (goodp erformers) and 182 patientsw ere less than 50% within this range (poorp erformers). For an INR range of 1.75 3.25, 294 were more than 80% within this range (good performers) and 101 patientsw ere less than 80% within this range (poor performers).
Relation between the percentage of time in rangea nd co-variables Simple models( withoutc orrection for other influences) showed no significant correlation between the percentage of time in the 2 3INR range and gender ( p / 0.13), the age of the patients(p / 0.06), the type of GP practice (single or group practice) ( p / 0.99), the anticoagulant used (phenprocoumon, acenocoumarol, warfarin) ( p / 0.43), the frequencyo ft ests/ patient ( p / 0.92), or the numbero fp atientso no ral anticoagulation/practice ( p / 0.14). As ignificant relation between the percentage of time in the 1.75 3.25 INR rangeand age was found ( p / 0.049). The variability between GP practices was 22%.
Event rates
Ta bleI Is hows the numbero ft hromboembolic and haemorrhagic events.T he incidence rate of minor bleeding was 14 per 100 patient years. There were six major bleeding events, representinga ni ncidence rate of 4.4 per 100 patient years. There were four thromboembolic events, representing an incidence rate of 2.9 per 100 patient years. In the logistic regression analysis, no significant relation between the presence of an event andh ypertension, diabetes mellitus,p rior strokeo rt ransient ischaemic attack, congestive heartfailure, myocardial infarction, valve disease, smoking habit, or ah istory of malignancy was found. In ar andom-effect logistic regression model, no significant relation between the presence of an event and patient performance withint he 2 3 INR range was found ( p / 0.056). As ignificant relation between the presence of an event and patient performance within the 1.75 3.25 INR range was found ( p / 0.017). The odds ratio for patient performance (poor versus good)a nd an event was 2.85 (95% CI 1.3 6.3). The relation between patient performance and thromboembolic events was not significant ( p / 0.9), but the relation between patient performance andh aemorrhagice vents was significant ( p / 0.02), with an odds ratio of 5.16 (SE 2.92).
Discussion
In ar etrospective cross-sectional study involving 66 GP practices, the INR valueso btained over a6 -mo period were analysed. Fifty-threeper cent of the day As ignificant relation between the presence of an event and patient performance (good versusp oor) was found, with an odds ratio for ah aemorrhagic event of 5.16.
The strength of this study is that all the INR analysesw ere performed in ones ingle clinical laboratory. Ac heck for possible inclusion bias of the participating GPs (response rate of 38% for all 255 GPs)s howed no significant difference in distribution ( p / 0.7) of the INRs between patients from participating and patientsfrom non-participating GPs. This study is limited by being ar etrospective cross-sectional study of general practice case records. Therefore, the datesofthe events were often missinga nd as urvival analysis could not be performed because no time-to-event was available. The analysest ol ook for ar elation between patient performance and the presence of an event are therefore only exploratory. Collection of the events occurred on av oluntaryb asis and couldh aveb een incomplete, especially regarding minor events.I n addition, no reliable information aboutc oncomitant medicationw as available. An additional strength of study is the fact that we first made al ist of all the INR analyses performed in the lab during the study period and sent the names of the corresponding patients to the GPs, so no patientso no ral anticoagulation were missed and the INRs were reliable.
The percentage of time within0 .5 INR of the target range was 53%, as proposed in British guidelines (5). In the literature, this percentage ranges from 53.2 86.3% (13 17) . Ac omparison between the British guidelines ando ur resultsw ithint he 1.75 3.25 INR range shows that the patients were 11% of the time less within the range than proposedb yt he guidelines (69% vs 80%) (5) . This study shows the importance of the latter quality criterion; it was in this group that as ignificant relation between poor performers (patients who were B / 80% of their time within this range) and the occurrence of ah aemorrhagice vent was found. Ah igh frequency of testing was found in our study, namely 2.7 per patient per month. However, no significant relation between the percentage of time in the 2 3INR range and the frequency of tests/patient was found. This implies that it is acceptable to test the INR in stable patientsmonthly to every6wk (5) . The high frequency of testing couldb ee xplained by GPs' fear of anticoagulation therapy,n amelye xcessiveI NRs and events due to therapy.E ducation on the guidelines of oral anticoagulation could increase the knowledge and self-confidence of GPs aboutthis therapy,a nd thus reduce the number of tests.
As tudy in the Netherlandsw ithin the anticoagulation clinics compared phenprocoumonv ersus acenocoumarol (6) . The authorsc oncluded that phenprocoumon leads to better quality regarding the percentage in range; no difference in occurrence of major bleedings was found. We could not confirm There was great variability in the percentage in range between GP practices,a lthought he quality of management of oral anticoagulation was not significantly different in single or groupp ractices, andt he quality of the management did not dependo nt he number of anticoagulant patientsp er GP practice. These results supportt he conclusion of ap revious published study that there is no evidence thatsinglepracticeG Ps are clinically underperforming (18) .
The incidence rate of major bleeding was 4.4 per 100 patient years, andp atients were only included after the first month of therapy.T he incidence rate for major bleeding was higher when comparing our data with data from ameta-analysis of 33 studies. In this study,t he incidence rate for patientsa fter the first 3m oo ft herapy was 2.7 per 100 patient years (95% CI 2.71 2.77) (19) . It is proven that the risk of haemorrhage increases when the INR is abovethe therapeutic range of 2.5 4.9 (3, 4) . In the European Atrial Fibrillation Trial, the incidence rate of haemorrhagicevents was 3per 100 patient yearsfor the overall group.This incidence rate rose to 50 per 100 patient yearswhenthe INR was above5 (20) . In that study,2 .6% of the INRs were / 5, compared to 2.8% in our study.H owever, the overall incidence rate for bleeding was significantly higherinour study (3 per 100 patient yearsv ersus4 .4 per 100 patient years). This could be explained by the higher age of our population, known to be ar isk factor for a haemorrhagice vent (21) . As ignificant relation between age andt he occurrence of an event was shown, with an odds ratio of 1.033 (95%CI1.007 1.061) for everya dditionaly ear in age (22) . The incidence rate fort hrombotic events was not substantially different from those (ranging from 3.5 3.9 per 100 patient years) in two available observational studies (17, 21) . Remarkably,i no ur study population, no significant relation between (historyo f) hypertension and the presence of bleeding was found. Possible explanations may be thatt he study sample was too small or that only patients with adequately controlled hypertension were enrolled.
Comparing these results with resultsi nt he literature, we conclude that the quality of monitoring oral anticoagulation by GPs in Belgium is suboptimal, as reflected by the distribution of INRs within the 1.75 3.25 INR range and the numbero fb leedings. Asignificant relation between poor performance and the occurrence of ah aemorrhagic event was found.
